Having to face up to more manufacturing issues as you are being sized up for a potential multi-billion buyout is not ideal, but that's the position Soliris' maker ...
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that it is initiating a voluntary recall of certain lots of Soliris(R) (eculizumab) 300 mg/30 mL concentrated solution for intravenous ...
CHESHIRE >> Alexion Pharmaceuticals is doing a voluntary recall and replacement of a limited number of vials of its drug Soliris, the company’s only approved drug. The company initiated the recall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results